Literature DB >> 26015856

Insights into cardio-oncology: Polypharmacology of quinazoline-based α1-adrenoceptor antagonists.

Salvatore Patanè1.   

Abstract

New uses of cardiovascular drugs with proven experience are emerging, including for treating cancer. Quinazoline is a compound made up of two fused six member simple aromatic rings, benzene and pyrimidine rings, with several biological effects. Cardiologists first used quinazoline-based α1-adrenoceptor antagonists prazosin, doxazosin, and terazosin; currently available data support their use as safe, well tolerated, and effective add-on therapy in uncontrolled hypertension with additional favourable metabolic effects. Recent findings highlight the anticancer effects of quinazoline-based α1-adrenoceptor antagonists, indicating that they may have a significant role in uncontrolled hypertensive cancer patients without signs of ischemia.

Entities:  

Keywords:  Cardio-oncology; Doxazosin; Multidrug resistance; Prazosin; Terazosin

Year:  2015        PMID: 26015856      PMCID: PMC4438465          DOI: 10.4330/wjc.v7.i5.238

Source DB:  PubMed          Journal:  World J Cardiol


  59 in total

1.  The chance finding of echocardiographic complications of infective endocarditis.

Authors:  Pietro Pugliatti; Cesare De Gregorio; Salvatore Patanè
Journal:  Int J Cardiol       Date:  2012-04-30       Impact factor: 4.164

2.  The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

Authors:  Paula T Einhorn; Barry R Davis; Barry M Massie; William C Cushman; Linda B Piller; Lara M Simpson; Daniel Levy; Chuke E Nwachuku; Henry R Black
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

3.  Contrast-enhancing right atrial thrombus in cancer patient.

Authors:  Pietro Pugliatti; Rocco Donato; Gianluca Di Bella; Scipione Carerj; Salvatore Patanè
Journal:  Int J Cardiol       Date:  2014-03-15       Impact factor: 4.164

4.  The war on cancer: time for a new terminology.

Authors:  Ian Haines
Journal:  Lancet       Date:  2014-05-31       Impact factor: 79.321

5.  Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies.

Authors:  Salvatore Patanè
Journal:  J Card Fail       Date:  2014-04-18       Impact factor: 5.712

6.  Prazosin induces p53-mediated autophagic cell death in H9C2 cells.

Authors:  Yi-Fan Yang; Chau-Chung Wu; Wen-Pin Chen; Yuh-Lien Chen; Ming-Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-26       Impact factor: 3.000

Review 7.  ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2014-06-11       Impact factor: 7.658

8.  Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.

Authors:  N Kyprianou; C M Benning
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

9.  Terazosin treatment induces caspase-3 expression in the rat ventral prostate.

Authors:  Georgios Papadopoulos; Dimitrios Vlachodimitropoulos; Aspasia Kyroudi; Mirsini Kouloukoussa; Despina Perrea; Dionisios Mitropoulos
Journal:  J Clin Med Res       Date:  2013-02-25

10.  A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.

Authors:  Aaron Petty; Eugene Myshkin; Haina Qin; Hong Guo; Hui Miao; Gregory P Tochtrop; Jer-Tsong Hsieh; Phillip Page; Lili Liu; Daniel J Lindner; Chayan Acharya; Alexander D MacKerell; Eckhard Ficker; Jianxing Song; Bingcheng Wang
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

View more
  1 in total

Review 1.  The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.

Authors:  Mallory Batty; Rachel Pugh; Ilampirai Rathinam; Joshua Simmonds; Edwin Walker; Amanda Forbes; Shailendra Anoopkumar-Dukie; Catherine M McDermott; Briohny Spencer; David Christie; Russ Chess-Williams
Journal:  Int J Mol Sci       Date:  2016-08-16       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.